Newsicon

8th December 2017

The Value of Collaboration in IBD

more »
29th November 2017

Tillotts Pharma Successfully Completes DCP1 for Colpermin™ in Europe

more »
10th November 2017

Rewarding the Extraordinary – an Evening at the Baloise Session

more »
11th October 2017

Tillotts Pharma: Positive Results of Largest Phase III Clinical Trial of Mesalazine Induction Therapy Published

more »
11th September 2017

A small fish in the big pond

more »
18th May 2017

Tillotts Pharma shows support for World IBD Day 2017

more »
25th April 2017

ECCO Satellite Symposium Report

more »
5th April 2017

Tillotts Pharma featured in Pharmaboardroom.com and Pharmaceutical Executive Magazine

more »
18th November 2016

Tillotts Pharma introduces OPTICORE™

more »
6th September 2016

Tillotts Pharma AG celebrates its 30th anniversary in Switzerland with the conference “Making Visions Happen”.

more »
6th September 2016

Tillotts Pharma opens in France and celebrates 30 Years anniversary.

more »
7th June 2016

Tillotts Pharma – 30 years of pioneering research in Switzerland

more »
9th June 2015

Tillotts Pharma AG under Agreement to Acquire Global Rights for Entocort® (budesonide) from AstraZeneca Outside the U.S.

more »
9th June 2015

Tillotts Pharma and Numab Announce Exclusive Development and Licensing Agreement

more »
1st May 2015

Tillotts Pharma supports the World IBD Day

more »
20th February 2015

Tillotts annouces results of European survey in ulcerative colitis

more »
9th January 2014

CPP, Inc. and Tillotts Pharma AG sign licensing agreement

more »

News Archive